TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05166746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Oral clindamycin 300mg/2xdaily in 7 days. LACTIN-V applicators 1x at night in 7 days, then 2xper week at night for 7 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Oral clindamycin 300mg/2xdaily in 7 days. LACTIN-V applicators 1x at night in 7 days, then 2xper week at night for 7 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Clindamycin placebo appear identical to active clindamycin by filling capsules with Mannitolium.~The LACTIN-V placebo product has no intrinsic effect and is used to study the effect of the therapeutically active product. It is supplied as a pre-filled vaginal applicator packaged under nitrogen gas with one desiccant packet (0.25 g) in a sealed foil pouch. Each applicator contains 200 mg of LACTIN-V placebo powder containing the inactive ingredients of the LACTIN-V drug product, but not Lactobacillus crispatus CTV-05 (CTV-05), the active ingedient. The excipients used in the manufacture of LACTIN-V placebo are identical to those in the LACTIN-V drug product. Each placebo applicator contains the following constituents: maltodextrin, trehalose, xylitol, colloidal silicon dioxide, and sodium ascorbate
Study: NCT01044680

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NUTRIOSE
Description: 17 grams of NUTRIOSE consumed twice daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 17 g maltodextrin consumed twice daily for 12 weeks
Study: NCT03144323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Four reminders will be set on the patient's mobile phone's Calendar-type app, saying Don't forget to wear your elastics, at 08:00, 13:00, 17:00 and 22:00.
Study: NCT00546039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genistein
Description: Capsule, 30 mg, oral daily for 3 to 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study: NCT02820883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus vaccine (60µg/per protein)
Description: two doses of 60µg/0.6ml per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus vaccine (30µg/per protein)
Description: two doses of 30µg/0.6ml per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus vaccine (15µg/per protein)
Description: two doses of 15µg/0.6ml per dose
Study: NCT03230474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine-Naloxone
Description: 50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\\ kg naloxone in 0.5 ml volume (total volume 2mL).
Study: NCT01257919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic Acid Foam
Description: Dermal application of Azelaic Acid Foam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelaic Acid Gel
Description: Dermal application of Azelaic Acid Gel
Study: NCT00790101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02137759

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Radiation Therapy
Description: Radiation therapy to 60 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Radiation Therapy
Description: Radiation therapy to 60 Gy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Temozolomide
Description: Temozolomide given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Temozolomide
Description: Temozolomide given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat dose to be determined, given intravenously over 30-45 minutes
Study: NCT02231294

Intervention type: DRUG
Intervention: Sifrol®
Study: NCT04153617

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control honey
Description: Control honey defined as orange blossom honey. Intake daily for 3 months (40 g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control honey
Description: Control honey defined as orange blossom honey. Intake daily for 3 months (40 g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Modified honey with soluble fiber and polyphenols
Description: Honey modified with soluble fiber and polyphenols, with same organoleptic conditions as control honey. Intake daily for 3 months (40 g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified honey with soluble fiber and polyphenols
Description: Honey modified with soluble fiber and polyphenols, with same organoleptic conditions as control honey. Intake daily for 3 months (40 g/day)
Study: NCT02849314

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
Study: NCT02351843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MECTA Spectrum 5000Q

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MECTA Spectrum 5000Q
Study: NCT00685061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: Induction
Study: NCT01417065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Starting dose will be 0.02 mg intravenous administered once on Day 1 over 60 minutes.
Study: NCT00000113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Addition Lenses
Description: Varilux comfort with +2.00 addition

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single vision lenses
Study: NCT01077388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietician electronic support
Description: Dietitian-delivered behavioral intervention, that uses a patient shared EMR and e-communications, will be integrated into routine healthcare and will result in improved control of modifiable CVD risk.
Study: NCT02090192

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WBV training

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WBV training

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRT training

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRT training
Study: NCT00685061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Induction
Study: NCT03634956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B. Sugammadex sodium-IONM
Description: Group B.the vagal nerve is detected and then 2 mg / kg of sugammadex sodium is administered to remove the muscle relaxant effect
Study: NCT04281784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHR-based Clinician Jumpstart
Description: The Jumpstart Guide is a communication-priming intervention for clinicians that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The one-page Jumpstart Guide provides information to the clinician about prior advance care planning documentation and code status derived from the EHR. The Jumpstart Guides includes tips to improve goals-of-care communication.
Study: NCT05215002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Call
Description: Patient will be called in the evening of the day of the surgery or one day after surgery and asked about any complaints

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No telephone call
Description: Patient will not be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
Study: NCT04762407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1910
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1910
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1909
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1909
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1903
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1903
Description: Take it once per period.
Study: NCT04117178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Adjustment of treatment with donepezil according to serum level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Adjustment of treatment with memantine according to serum level.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of serum level of anti-dementia drug
Description: Participants allocated to the intervention arm are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention group not experiencing side effects will have their treatment adjusted after 6 months based upon serum levels of the drug in question.~Participants allocated to the standard of care arm follow the usual routines of the dementia clinic but are requested to have the serum level of the prescribed drug and CYP2D6-genotype measured after 12 month.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of serum level of anti-dementia drug
Description: Participants allocated to the intervention arm are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention group not experiencing side effects will have their treatment adjusted after 6 months based upon serum levels of the drug in question.~Participants allocated to the standard of care arm follow the usual routines of the dementia clinic but are requested to have the serum level of the prescribed drug and CYP2D6-genotype measured after 12 month.
Study: NCT03975374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin/dexamethasone opthalmic solution
Description: To compare efficacy and safety in randomized patients recieving Tobradex versus Tobramycin/Dexamethasone opthamic Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobradex Opthalmic Solution
Description: Tobradex Opthalmic Solution
Study: NCT03935165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: 0.25 mg /(kg BW) Indocyanine Green PULSION®/ VERDYE Diagnostic Green®~- Indocyanine Green is administered Intravenously
Study: NCT03497234

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Perilynx Analyzer to measure AF and VF fluid
Description: Hologic developed a rapid in-vitro diagnostic system composed of an analyzer and cassettes to identify women with intra-amniotic infection.
Study: NCT00082758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu14.18-Interleukin-2 fusion protein
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu14.18-Interleukin-2 fusion protein
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu14.18-Interleukin-2 fusion protein
Description: Given IV
Study: NCT03179007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CTLA-4/PD-1 expressing MUC1-CAR-T
Description: Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing MUC1 targeted CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
Study: NCT03596658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR9549
Description: If initial dosing of SHR9549 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose(MTD) is defined
Study: NCT03743233

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand file
Description: A crown-down technique will be performed until reaching the provisory WL. The root canals will be initially deobstructed with size #3 and #2 Gates-Glidden burs (Dentsply-Maillefer) at the coronal and middle root thirds. Then, hand stainless steel K-files (Dentsply-Maillefer) with decreasing sizes will be used (#40, #35, #30, #25). The WL will be determined by an electronic apex locator (Novapex; Forum Technologies, Rishon Le-Zion, Israel). A radiograph will be taken to confirm the WL, which should be 1 mm short of the root apex. Apical patency will be reached and maintained with a size #15 K-file (Dentsply-Maillefer). The root canals will be reinstrumented and a size #50 K-file will be standardized as the master apical instrument. A step-back procedure in 1-mm increments followed until merging with the crown-down rotary enlargement (size #70) will be achieved.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reciprocating
Description: Reciproc R25 file will be used for gutta-percha removal, until reaching the WL. The instrument will be introduced into the canal applying slight movements of 3-mm amplitude. Apical patency will be maintained with a size #15 K-file. The root canals will be reinstrumented using the Reciproc R50 file. For both groups, after the root canal filling removal and reinstrumentation protocol, a new radiograph will be taken, without any intracanal instrument, for posterior analysis of the percentage of remaining filling material in the root canal. If the radiograph demonstrates the persistence of filling material, the technique will be repeated with the last instrument used in the chemomechanical preparation (hand or reciprocating file), also using H-files with circumferential movements against the dentinal walls in order to remove these residual material, followed by abundant irrigation with NaOCl.
Study: NCT00646126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)
Description: Standard three day regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet similar to active drug in shape and size
Description: Dosage similar to active drug(standard three days regimen)
Study: NCT04255771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard GC (gemcitabine and cisplatin) regimen: gemcitabine 1000-1200mg/m2 intravenous infusion on days 1 and 8, cisplatin 70mg/m2 on the second day of intravenous infusion, every 3 weeks (21-day regimen) is a cycle, A total of 3 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Use a placebo as a comparison
Study: NCT03200470

Intervention type: OTHER
Intervention: No intervention: sample collection study
Description: Sample collection and collection of laboratory values
Study: NCT04032158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avonex®
Description: Participants received avonex® IM injection once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex® matched Placebo
Description: Participants received IM injection of placebo matched to Avonex® once a week.
Study: NCT03997864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved, max dose is reached, or side effects are problematic.~Tapering Decrease prazosin 1 mg every 3 days or 3 mgs per week until off completely. Tapering will take approximately 2-3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved max dose is reached, or side effects are problematic.
Study: NCT01302184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat®
Description: Patients of the experimental group were trained at 50% of BWS for 15 minutes and 30% of BWS for 15 minutes on the Lokomat®. Treadmill speed was initiated at 1.5km/h and increased to 3.0km/h by increments of 0.5km/h as tolerated.~A physical therapist supervised the treatment, adjusting treadmill speed and BWS.~Treatment was performed for 3 days/week, for 4 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Description: Patients of the control group had 30 minutes of treadmill gait training. After having calculated the speed during 6MWT, the patient was trained on a treadmill (RHC770CE - RAM Medical srl). They were trained using 80% of the maximum speed that the patient reached during the test for the first week, 90% for the second week, 100% for the third and fourth week.~A Physical Therapist provided auditory cueing and direct, continuous feed-back to the patient.~Treatment was performed for 3 days/week, for 4 weeks.
Study: NCT04456907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: Autologous platelet-rich plasma (PRP) was prepared using the RegenKit THT system (RegenLab SA, Le Mont-sur-Lausanne, Switzerland) following the manufacturer's instructions. Medical technicians, who had been well-trained by the manufacturer, were responsible for the process of PRP preparation. For each patient, 8-10 mL of venous blood was drawn and collected to the commercial RegnLab THT tube, which contained 1 mL sodium citrate. After single centrifugation at 3400 revolutions per minute (rpm) for 8 minutes, 4-5 mL of PRP was yielded with leukocytes maintained at physiological levels and red blood cells depleted. Then, the blood components were separated, with the platelet pellet resting on the separating gel. PRP for later application was obtained by re-suspending the platelet pellet in the plasma supernatant by gently inverting the unopened RegenKit THT tube 5 to 10 times.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: saline injection
Description: saline injection
Study: NCT03089814

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ischemic conditioning
Description: Four cycles of 5-min inflation of pneumatic cuff on upper extremity up to 200 mmHg, followed by 5-min deflation with no pressure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ischemic conditioning
Description: Four cycles of 5-min inflation of pneumatic cuff on upper extremity up to 200 mmHg, followed by 5-min deflation with no pressure.
Study: NCT04373421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate 0.12 % Mouthwash + benzydamine hydrochloride
Description: After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: St. John's wort oil
Description: After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Virgin olive oil
Description: After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
Study: NCT01877174

Intervention type: DEVICE
Intervention: MICHI(TM) NPS+f
Description: Transcarotid delivery system for carotid stents with flow reversal

Intervention type: PROCEDURE
Intervention: transcarotid stenting